NADAC acquisition cost data for INTELENCE 200 MG TABLET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 59676057101 | $23.39 | 2022-04-20 | Rx |
| 59676057101 | $23.39 | 2022-04-20 | Rx |
| 59676057101 | $23.39 | 2022-04-20 | Rx |
| 59676057101 | $23.39 | 2022-04-20 | Rx |
| 59676057101 | $23.39 | 2022-04-20 | Rx |
| 59676057101 | $23.39 | 2022-04-20 | Rx |
| 59676057101 | $23.39 | 2022-04-20 | Rx |
| 59676057101 | $23.39 | 2022-04-20 | Rx |
| 59676057101 | $23.39 | 2022-04-20 | Rx |
| 59676057101 | $23.39 | 2022-04-20 | Rx |
Generic: Etravirine | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $80.1M | 54,149 | 6,403 | $22.07 |
| 2020 | $68.2M | 43,768 | 4,971 | $22.53 |
| 2021 | $46.9M | 30,054 | 4,148 | $23.42 |
| 2022 | $12.9M | 8,554 | 1,557 | $23.67 |
| 2023 | $4.7M | 3,100 | 590 | $23.29 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $1.3M | 842 | 153 |
| Florida | $733.4K | 517 | 93 |
| Texas | $367.0K | 241 | 48 |
| California | $219.0K | 141 | 44 |
| Georgia | $210.9K | 132 | 29 |
| North Carolina | $141.4K | 91 | 11 |
| Pennsylvania | $132.1K | 81 | 14 |
| Illinois | $119.0K | 53 | 12 |
| Virginia | $110.7K | 75 | 12 |
| New Jersey | $110.0K | 69 | N/A |
| Kentucky | $108.3K | 73 | 12 |
| Massachusetts | $104.7K | 67 | 16 |
| Michigan | $92.7K | 69 | 14 |
| Colorado | $83.3K | 67 | N/A |
| Louisiana | $69.8K | 48 | N/A |
| Tennessee | $68.1K | 47 | N/A |
| Washington | $54.7K | 41 | N/A |
| Arizona | $50.4K | 34 | N/A |
| Mississippi | $42.4K | 35 | N/A |
| Indiana | $41.6K | 22 | N/A |
| Oregon | $39.3K | 26 | N/A |
| Hawaii | $38.8K | 20 | N/A |
| Ohio | $38.5K | 25 | N/A |
| Wisconsin | $33.1K | 26 | N/A |
| Maryland | $32.3K | 21 | N/A |
| Alabama | $31.4K | 26 | N/A |
| West Virginia | $29.3K | 20 | N/A |
| Puerto Rico | $26.3K | 18 | N/A |
| South Carolina | $24.9K | 19 | N/A |
| Minnesota | $23.9K | 15 | N/A |
| Missouri | $23.1K | 15 | N/A |
| Delaware | $21.5K | 14 | N/A |
| District of Columbia | $20.2K | 13 | N/A |
| Nebraska | $19.6K | 12 | N/A |
| New Mexico | $19.5K | 12 | N/A |
| South Dakota | $17.2K | 11 | N/A |
| Kansas | $14.4K | 11 | N/A |
| Iowa | $13.8K | 11 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.